Enhancing exercise response in obstructive HCM: insights from aficamten's impact on patients with obstructive hypertrophic cardiomyopathy in SEQUOIA-HCM

13 May 2024 (14:21 - 14:29)

Organised by:

Video

Sign in for access options

Slides

About the speaker

Doctor Gregory D Lewis

Massachusetts General Hospital, Boston (United States of America)

9 More presentations in this session

Presentation thumbnail

Outcomes with aspirin avoidance after implantation of a Fully Magnetically Levitated LVAD in patients with coronary, cerebral or peripheral vascular disease: the ARIES HM3 randomized clinical trial

Professor F. Gustafsson (Pleasanton, US)

Presentation thumbnail

Discussant review - ARIES

Doctor O. Dar (London, GB)

Presentation thumbnail

Semaglutide therapy and diuretic use in obesity-related HFpEF: insights from the STEP-HFpEF programme

Professor S. Verma (Toronto, CA)

Presentation thumbnail

Discussant review - STEP-HFpEF Programme

Assistant Professor D. Farmakis (Athens, GR)

Presentation thumbnail

Aficamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy: SEQUOIA-HCM an international multicenter phase 3 trial

Doctor M. Maron (Burlington, US)

Access the full session

Session thumbnail

Late breaking clinical trials: LVAD, HFpEF and hypertrophic cardiomyopathy

The Event

Event poster

Heart Failure 2024

13 May 2024 14:21 CET

You may be interested in

Congress Presentation

Discussant review - SEQUOIA-HCM: Aficamten’s impact on exercise response in obstructive HCM

Congress Session

Late breaking clinical trials: LVAD, HFpEF and hypertrophic cardiomyopathy

Congress Presentation

Aficamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy: SEQUOIA-HCM an international multicenter phase 3 trial

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources